FULCRUM THERAPEUTICS INC (FULC) Fundamental Analysis & Valuation

NASDAQ:FULC • US3596161097

7.87 USD
+0.06 (+0.77%)
At close: Mar 3, 2026
7.82 USD
-0.05 (-0.64%)
Pre-Market: 3/4/2026, 4:21:43 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This FULC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

FULC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While FULC has a great health rating, there are worries on its profitability. FULC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. FULC Profitability Analysis

1.1 Basic Checks

  • In the past year FULC has reported negative net income.
  • In the past year FULC has reported a negative cash flow from operations.
  • In the past 5 years FULC always reported negative net income.
  • In the past 5 years FULC always reported negative operating cash flow.
FULC Yearly Net Income VS EBIT VS OCF VS FCFFULC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • FULC has a better Return On Assets (-20.44%) than 61.14% of its industry peers.
  • FULC's Return On Equity of -21.46% is fine compared to the rest of the industry. FULC outperforms 67.88% of its industry peers.
Industry RankSector Rank
ROA -20.44%
ROE -21.46%
ROIC N/A
ROA(3y)-20.65%
ROA(5y)-28.96%
ROE(3y)-22.28%
ROE(5y)-32.06%
ROIC(3y)N/A
ROIC(5y)N/A
FULC Yearly ROA, ROE, ROICFULC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K -1.5K

1.3 Margins

  • FULC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FULC Yearly Profit, Operating, Gross MarginsFULC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. FULC Health Analysis

2.1 Basic Checks

  • FULC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • FULC has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, FULC has more shares outstanding
  • FULC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FULC Yearly Shares OutstandingFULC Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
FULC Yearly Total Debt VS Total AssetsFULC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • FULC has an Altman-Z score of 16.29. This indicates that FULC is financially healthy and has little risk of bankruptcy at the moment.
  • FULC has a Altman-Z score of 16.29. This is amongst the best in the industry. FULC outperforms 86.01% of its industry peers.
  • There is no outstanding debt for FULC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.29
ROIC/WACCN/A
WACC9.18%
FULC Yearly LT Debt VS Equity VS FCFFULC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 27.40 indicates that FULC has no problem at all paying its short term obligations.
  • FULC has a better Current ratio (27.40) than 94.82% of its industry peers.
  • A Quick Ratio of 27.40 indicates that FULC has no problem at all paying its short term obligations.
  • The Quick ratio of FULC (27.40) is better than 94.82% of its industry peers.
Industry RankSector Rank
Current Ratio 27.4
Quick Ratio 27.4
FULC Yearly Current Assets VS Current LiabilitesFULC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. FULC Growth Analysis

3.1 Past

  • FULC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -436.36%.
  • Looking at the last year, FULC shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-436.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, FULC will show a very strong growth in Earnings Per Share. The EPS will grow by 23.44% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.72%
EPS Next 2Y-16.57%
EPS Next 3Y4.15%
EPS Next 5Y23.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FULC Yearly Revenue VS EstimatesFULC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
FULC Yearly EPS VS EstimatesFULC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. FULC Valuation Analysis

4.1 Price/Earnings Ratio

  • FULC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year FULC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FULC Price Earnings VS Forward Price EarningsFULC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FULC Per share dataFULC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.57%
EPS Next 3Y4.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FULC Dividend Analysis

5.1 Amount

  • FULC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

FULC Fundamentals: All Metrics, Ratios and Statistics

FULCRUM THERAPEUTICS INC

NASDAQ:FULC (3/3/2026, 8:14:36 PM)

Premarket: 7.82 -0.05 (-0.64%)

7.87

+0.06 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)04-29
Inst Owners75.43%
Inst Owner Change23.06%
Ins Owners0.51%
Ins Owner Change-1.03%
Market Cap524.14M
Revenue(TTM)N/A
Net Income(TTM)-74.88M
Analysts81.25
Price Target19.38 (146.25%)
Short Float %5.35%
Short Ratio3.88
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.9%
Min EPS beat(2)-3.46%
Max EPS beat(2)1.67%
EPS beat(4)3
Avg EPS beat(4)2.55%
Min EPS beat(4)-3.46%
Max EPS beat(4)6.63%
EPS beat(8)7
Avg EPS beat(8)869.77%
EPS beat(12)11
Avg EPS beat(12)583.84%
EPS beat(16)12
Avg EPS beat(16)437.57%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)39.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.5
P/tB 1.5
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.31
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0
BVpS5.24
TBVpS5.24
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.44%
ROE -21.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-20.65%
ROA(5y)-28.96%
ROE(3y)-22.28%
ROE(5y)-32.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.4
Quick Ratio 27.4
Altman-Z 16.29
F-Score3
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)21.14%
Cap/Depr(5y)42.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-436.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-10.72%
EPS Next 2Y-16.57%
EPS Next 3Y4.15%
EPS Next 5Y23.44%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-327.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.61%
EBIT Next 3Y-20.27%
EBIT Next 5YN/A
FCF growth 1Y-2319.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-2608.07%
OCF growth 3YN/A
OCF growth 5YN/A

FULCRUM THERAPEUTICS INC / FULC FAQ

What is the fundamental rating for FULC stock?

ChartMill assigns a fundamental rating of 3 / 10 to FULC.


What is the valuation status of FULCRUM THERAPEUTICS INC (FULC) stock?

ChartMill assigns a valuation rating of 0 / 10 to FULCRUM THERAPEUTICS INC (FULC). This can be considered as Overvalued.


Can you provide the profitability details for FULCRUM THERAPEUTICS INC?

FULCRUM THERAPEUTICS INC (FULC) has a profitability rating of 1 / 10.


How financially healthy is FULCRUM THERAPEUTICS INC?

The financial health rating of FULCRUM THERAPEUTICS INC (FULC) is 8 / 10.


Can you provide the expected EPS growth for FULC stock?

The Earnings per Share (EPS) of FULCRUM THERAPEUTICS INC (FULC) is expected to decline by -10.72% in the next year.